Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7866496 | 0.90 | REN (0.62) | RENKCNH2 | |
| SCHEMBL13985785 | 0.88 | REN (0.60) | REN | |
| SCHEMBL7866491 | 0.86 | REN (1.00) | RENKCNH2 | |
| SCHEMBL7858464 | 0.85 | REN (0.74) | RENKCNH2 | |
| SCHEMBL7869506 | 0.84 | REN (0.75) | RENKCNH2 | |
| SCHEMBL7869570 | 0.83 | REN (0.73) | REN | |
| SCHEMBL7866437 | 0.81 | REN (0.73) | RENKCNH2 | |
| SCHEMBL7864053 | 0.79 | REN (0.72) | RENKCNH2 | |
| SCHEMBL13985762 | 0.79 | REN (0.49) | REN | |
| SCHEMBL7865222 | 0.77 | REN (0.72) | RENKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497286-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-8383650-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | disclosed |
| US-20130005770-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080319018-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319018-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885KCNH2 986/4885 |
| US-20130005770-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | REN 1/4885KCNH2 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.